Research Methodology

The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:

★Stage 1 SECONDARY RESEARCH

The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.

★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES

After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.

★Stage 3 ANALYSIS OF THE GATHERED DATA

The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.

★Stage 4 QUANTITATIVE DATA

The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.

★Stage 5 QUALITY CONTROL

Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.

1 Blood Cancer Treatments Market Overview
1.1 Product Definition
1.2 Blood Cancer Treatments by Type
1.2.1 Global Blood Cancer Treatments Market Value by Type: 2025 vs 2032
1.2.2 Chemotherapy
1.2.3 Targeted Therapy
1.2.4 Immunotherapy (Biologic Therapy)
1.2.5 Hormonal Therapy
1.2.6 Others
1.3 Blood Cancer Treatments by Application
1.3.1 Global Blood Cancer Treatments Market Value by Application: 2025 vs 2032
1.3.2 Leukemia
1.3.3 lymphoma
1.3.4 Myeloma
1.3.5 Others
1.4 Global Blood Cancer Treatments Market Size Estimates and Forecasts
1.4.1 Global Blood Cancer Treatments Revenue 2021–2032
1.4.2 Global Blood Cancer Treatments Sales 2021–2032
1.4.3 Global Blood Cancer Treatments Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Blood Cancer Treatments Market Competition by Manufacturers
2.1 Global Blood Cancer Treatments Sales Market Share by Manufacturers (2021–2026)
2.2 Global Blood Cancer Treatments Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Blood Cancer Treatments Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Blood Cancer Treatments, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Blood Cancer Treatments, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Blood Cancer Treatments, Product Types and Applications
2.7 Global Key Manufacturers of Blood Cancer Treatments, Date of Entry into the Industry
2.8 Global Blood Cancer Treatments Market Competitive Situation and Trends
2.8.1 Global Blood Cancer Treatments Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Blood Cancer Treatments Players Market Share by Revenue
2.8.3 Global Blood Cancer Treatments Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Blood Cancer Treatments Market Scenario by Region
3.1 Global Blood Cancer Treatments Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Blood Cancer Treatments Sales by Region: 2021–2032
3.2.1 Global Blood Cancer Treatments Sales by Region: 2021–2026
3.2.2 Global Blood Cancer Treatments Sales by Region: 2027–2032
3.3 Global Blood Cancer Treatments Revenue by Region: 2021–2032
3.3.1 Global Blood Cancer Treatments Revenue by Region: 2021–2026
3.3.2 Global Blood Cancer Treatments Revenue by Region: 2027–2032
3.4 North America Blood Cancer Treatments Market Facts & Figures by Country
3.4.1 North America Blood Cancer Treatments Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Blood Cancer Treatments Sales by Country (2021–2032)
3.4.3 North America Blood Cancer Treatments Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Blood Cancer Treatments Market Facts & Figures by Country
3.5.1 Europe Blood Cancer Treatments Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Blood Cancer Treatments Sales by Country (2021–2032)
3.5.3 Europe Blood Cancer Treatments Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Blood Cancer Treatments Market Facts & Figures by Region
3.6.1 Asia Pacific Blood Cancer Treatments Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Blood Cancer Treatments Sales by Region (2021–2032)
3.6.3 Asia Pacific Blood Cancer Treatments Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Blood Cancer Treatments Market Facts & Figures by Country
3.7.1 Latin America Blood Cancer Treatments Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Blood Cancer Treatments Sales by Country (2021–2032)
3.7.3 Latin America Blood Cancer Treatments Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Blood Cancer Treatments Market Facts & Figures by Country
3.8.1 Middle East and Africa Blood Cancer Treatments Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Blood Cancer Treatments Sales by Country (2021–2032)
3.8.3 Middle East and Africa Blood Cancer Treatments Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Blood Cancer Treatments Sales by Type (2021–2032)
4.1.1 Global Blood Cancer Treatments Sales by Type (2021–2026)
4.1.2 Global Blood Cancer Treatments Sales by Type (2027–2032)
4.1.3 Global Blood Cancer Treatments Sales Market Share by Type (2021–2032)
4.2 Global Blood Cancer Treatments Revenue by Type (2021–2032)
4.2.1 Global Blood Cancer Treatments Revenue by Type (2021–2026)
4.2.2 Global Blood Cancer Treatments Revenue by Type (2027–2032)
4.2.3 Global Blood Cancer Treatments Revenue Market Share by Type (2021–2032)
4.3 Global Blood Cancer Treatments Price by Type (2021–2032)
5 Segment by Application
5.1 Global Blood Cancer Treatments Sales by Application (2021–2032)
5.1.1 Global Blood Cancer Treatments Sales by Application (2021–2026)
5.1.2 Global Blood Cancer Treatments Sales by Application (2027–2032)
5.1.3 Global Blood Cancer Treatments Sales Market Share by Application (2021–2032)
5.2 Global Blood Cancer Treatments Revenue by Application (2021–2032)
5.2.1 Global Blood Cancer Treatments Revenue by Application (2021–2026)
5.2.2 Global Blood Cancer Treatments Revenue by Application (2027–2032)
5.2.3 Global Blood Cancer Treatments Revenue Market Share by Application (2021–2032)
5.3 Global Blood Cancer Treatments Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Roche
6.1.1 Roche Company Information
6.1.2 Roche Description and Business Overview
6.1.3 Roche Blood Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Roche Blood Cancer Treatments Product Portfolio
6.1.5 Roche Recent Developments/Updates
6.2 Celgene
6.2.1 Celgene Company Information
6.2.2 Celgene Description and Business Overview
6.2.3 Celgene Blood Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Celgene Blood Cancer Treatments Product Portfolio
6.2.5 Celgene Recent Developments/Updates
6.3 Novartis
6.3.1 Novartis Company Information
6.3.2 Novartis Description and Business Overview
6.3.3 Novartis Blood Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Novartis Blood Cancer Treatments Product Portfolio
6.3.5 Novartis Recent Developments/Updates
6.4 Bristol-Myers Squibb
6.4.1 Bristol-Myers Squibb Company Information
6.4.2 Bristol-Myers Squibb Description and Business Overview
6.4.3 Bristol-Myers Squibb Blood Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Bristol-Myers Squibb Blood Cancer Treatments Product Portfolio
6.4.5 Bristol-Myers Squibb Recent Developments/Updates
6.5 Johnson & Johnson
6.5.1 Johnson & Johnson Company Information
6.5.2 Johnson & Johnson Description and Business Overview
6.5.3 Johnson & Johnson Blood Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Johnson & Johnson Blood Cancer Treatments Product Portfolio
6.5.5 Johnson & Johnson Recent Developments/Updates
6.6 Merck & Co.
6.6.1 Merck & Co. Company Information
6.6.2 Merck & Co. Description and Business Overview
6.6.3 Merck & Co. Blood Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Merck & Co. Blood Cancer Treatments Product Portfolio
6.6.5 Merck & Co. Recent Developments/Updates
6.7 AstraZeneca
6.7.1 AstraZeneca Company Information
6.7.2 AstraZeneca Description and Business Overview
6.7.3 AstraZeneca Blood Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 AstraZeneca Blood Cancer Treatments Product Portfolio
6.7.5 AstraZeneca Recent Developments/Updates
6.8 Pfizer
6.8.1 Pfizer Company Information
6.8.2 Pfizer Description and Business Overview
6.8.3 Pfizer Blood Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Pfizer Blood Cancer Treatments Product Portfolio
6.8.5 Pfizer Recent Developments/Updates
6.9 Amgen
6.9.1 Amgen Company Information
6.9.2 Amgen Description and Business Overview
6.9.3 Amgen Blood Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Amgen Blood Cancer Treatments Product Portfolio
6.9.5 Amgen Recent Developments/Updates
6.10 Eli Lilly
6.10.1 Eli Lilly Company Information
6.10.2 Eli Lilly Description and Business Overview
6.10.3 Eli Lilly Blood Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Eli Lilly Blood Cancer Treatments Product Portfolio
6.10.5 Eli Lilly Recent Developments/Updates
6.11 AbbVie
6.11.1 AbbVie Company Information
6.11.2 AbbVie Description and Business Overview
6.11.3 AbbVie Blood Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 AbbVie Blood Cancer Treatments Product Portfolio
6.11.5 AbbVie Recent Developments/Updates
6.12 Takeda
6.12.1 Takeda Company Information
6.12.2 Takeda Description and Business Overview
6.12.3 Takeda Blood Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 Takeda Blood Cancer Treatments Product Portfolio
6.12.5 Takeda Recent Developments/Updates
6.13 Astellas
6.13.1 Astellas Company Information
6.13.2 Astellas Description and Business Overview
6.13.3 Astellas Blood Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 Astellas Blood Cancer Treatments Product Portfolio
6.13.5 Astellas Recent Developments/Updates
6.14 Ipsen
6.14.1 Ipsen Company Information
6.14.2 Ipsen Description and Business Overview
6.14.3 Ipsen Blood Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.14.4 Ipsen Blood Cancer Treatments Product Portfolio
6.14.5 Ipsen Recent Developments/Updates
6.15 Sanofi
6.15.1 Sanofi Company Information
6.15.2 Sanofi Description and Business Overview
6.15.3 Sanofi Blood Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.15.4 Sanofi Blood Cancer Treatments Product Portfolio
6.15.5 Sanofi Recent Developments/Updates
6.16 Bayer
6.16.1 Bayer Company Information
6.16.2 Bayer Description and Business Overview
6.16.3 Bayer Blood Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.16.4 Bayer Blood Cancer Treatments Product Portfolio
6.16.5 Bayer Recent Developments/Updates
6.17 Biogen Idec
6.17.1 Biogen Idec Company Information
6.17.2 Biogen Idec Description and Business Overview
6.17.3 Biogen Idec Blood Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.17.4 Biogen Idec Blood Cancer Treatments Product Portfolio
6.17.5 Biogen Idec Recent Developments/Updates
6.18 Teva
6.18.1 Teva Company Information
6.18.2 Teva Description and Business Overview
6.18.3 Teva Blood Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.18.4 Teva Blood Cancer Treatments Product Portfolio
6.18.5 Teva Recent Developments/Updates
6.19 Otsuka
6.19.1 Otsuka Company Information
6.19.2 Otsuka Description and Business Overview
6.19.3 Otsuka Blood Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.19.4 Otsuka Blood Cancer Treatments Product Portfolio
6.19.5 Otsuka Recent Developments/Updates
6.20 Eisai
6.20.1 Eisai Company Information
6.20.2 Eisai Description and Business Overview
6.20.3 Eisai Blood Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.20.4 Eisai Blood Cancer Treatments Product Portfolio
6.20.5 Eisai Recent Developments/Updates
6.21 Merck KGaA
6.21.1 Merck KGaA Company Information
6.21.2 Merck KGaA Description and Business Overview
6.21.3 Merck KGaA Blood Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.21.4 Merck KGaA Blood Cancer Treatments Product Portfolio
6.21.5 Merck KGaA Recent Developments/Updates
6.22 Gilead Sciences
6.22.1 Gilead Sciences Company Information
6.22.2 Gilead Sciences Description and Business Overview
6.22.3 Gilead Sciences Blood Cancer Treatments Sales, Revenue, and Gross Margin (2021–2026)
6.22.4 Gilead Sciences Blood Cancer Treatments Product Portfolio
6.22.5 Gilead Sciences Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Blood Cancer Treatments Industry Chain Analysis
7.2 Blood Cancer Treatments Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Blood Cancer Treatments Production Mode & Process Analysis
7.4 Blood Cancer Treatments Sales and Marketing
7.4.1 Blood Cancer Treatments Sales Channels
7.4.2 Blood Cancer Treatments Distributors
7.5 Blood Cancer Treatments Customer Analysis
8 Blood Cancer Treatments Market Dynamics
8.1 Blood Cancer Treatments Industry Trends
8.2 Blood Cancer Treatments Market Drivers
8.3 Blood Cancer Treatments Market Challenges
8.4 Blood Cancer Treatments Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Tables
Table 1. Global Blood Cancer Treatments Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Blood Cancer Treatments Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Blood Cancer Treatments Market Competitive Situation by Manufacturers in 2025
Table 4. Global Blood Cancer Treatments Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Blood Cancer Treatments Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Blood Cancer Treatments Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Blood Cancer Treatments Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Blood Cancer Treatments Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Blood Cancer Treatments, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Blood Cancer Treatments, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Blood Cancer Treatments, Product Types and Applications
Table 12. Global Key Manufacturers of Blood Cancer Treatments, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Blood Cancer Treatments Companies by Tier (Tier 1, Tier 2, Tier 3), based on Blood Cancer Treatments Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Blood Cancer Treatments Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Blood Cancer Treatments Sales by Region (K Units), 2021–2026
Table 18. Global Blood Cancer Treatments Sales Market Share by Region (2021–2026)
Table 19. Global Blood Cancer Treatments Sales by Region (K Units), 2027–2032
Table 20. Global Blood Cancer Treatments Sales Market Share by Region (2027–2032)
Table 21. Global Blood Cancer Treatments Revenue by Region (US$ Million), 2021–2026
Table 22. Global Blood Cancer Treatments Revenue Market Share by Region (2021–2026)
Table 23. Global Blood Cancer Treatments Revenue by Region (US$ Million), 2027–2032
Table 24. Global Blood Cancer Treatments Revenue Market Share by Region (2027–2032)
Table 25. North America Blood Cancer Treatments Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Blood Cancer Treatments Sales by Country (K Units), 2021–2026
Table 27. North America Blood Cancer Treatments Sales by Country (K Units), 2027–2032
Table 28. North America Blood Cancer Treatments Revenue by Country (US$ Million), 2021–2026
Table 29. North America Blood Cancer Treatments Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Blood Cancer Treatments Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Blood Cancer Treatments Sales by Country (K Units), 2021–2026
Table 32. Europe Blood Cancer Treatments Sales by Country (K Units), 2027–2032
Table 33. Europe Blood Cancer Treatments Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Blood Cancer Treatments Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Blood Cancer Treatments Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Blood Cancer Treatments Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Blood Cancer Treatments Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Blood Cancer Treatments Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Blood Cancer Treatments Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Blood Cancer Treatments Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Blood Cancer Treatments Sales by Country (K Units), 2021–2026
Table 42. Latin America Blood Cancer Treatments Sales by Country (K Units), 2027–2032
Table 43. Latin America Blood Cancer Treatments Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Blood Cancer Treatments Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Blood Cancer Treatments Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Blood Cancer Treatments Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Blood Cancer Treatments Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Blood Cancer Treatments Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Blood Cancer Treatments Revenue by Country (US$ Million), 2027–2032
Table 50. Global Blood Cancer Treatments Sales (K Units) by Type (2021–2026)
Table 51. Global Blood Cancer Treatments Sales (K Units) by Type (2027–2032)
Table 52. Global Blood Cancer Treatments Sales Market Share by Type (2021–2026)
Table 53. Global Blood Cancer Treatments Sales Market Share by Type (2027–2032)
Table 54. Global Blood Cancer Treatments Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Blood Cancer Treatments Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Blood Cancer Treatments Revenue Market Share by Type (2021–2026)
Table 57. Global Blood Cancer Treatments Revenue Market Share by Type (2027–2032)
Table 58. Global Blood Cancer Treatments Price (US$/Unit) by Type (2021–2026)
Table 59. Global Blood Cancer Treatments Price (US$/Unit) by Type (2027–2032)
Table 60. Global Blood Cancer Treatments Sales (K Units) by Application (2021–2026)
Table 61. Global Blood Cancer Treatments Sales (K Units) by Application (2027–2032)
Table 62. Global Blood Cancer Treatments Sales Market Share by Application (2021–2026)
Table 63. Global Blood Cancer Treatments Sales Market Share by Application (2027–2032)
Table 64. Global Blood Cancer Treatments Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Blood Cancer Treatments Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Blood Cancer Treatments Revenue Market Share by Application (2021–2026)
Table 67. Global Blood Cancer Treatments Revenue Market Share by Application (2027–2032)
Table 68. Global Blood Cancer Treatments Price (US$/Unit) by Application (2021–2026)
Table 69. Global Blood Cancer Treatments Price (US$/Unit) by Application (2027–2032)
Table 70. Roche Company Information
Table 71. Roche Description and Business Overview
Table 72. Roche Blood Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Roche Blood Cancer Treatments Product
Table 74. Roche Recent Developments/Updates
Table 75. Celgene Company Information
Table 76. Celgene Description and Business Overview
Table 77. Celgene Blood Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Celgene Blood Cancer Treatments Product
Table 79. Celgene Recent Developments/Updates
Table 80. Novartis Company Information
Table 81. Novartis Description and Business Overview
Table 82. Novartis Blood Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Novartis Blood Cancer Treatments Product
Table 84. Novartis Recent Developments/Updates
Table 85. Bristol-Myers Squibb Company Information
Table 86. Bristol-Myers Squibb Description and Business Overview
Table 87. Bristol-Myers Squibb Blood Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Bristol-Myers Squibb Blood Cancer Treatments Product
Table 89. Bristol-Myers Squibb Recent Developments/Updates
Table 90. Johnson & Johnson Company Information
Table 91. Johnson & Johnson Description and Business Overview
Table 92. Johnson & Johnson Blood Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. Johnson & Johnson Blood Cancer Treatments Product
Table 94. Johnson & Johnson Recent Developments/Updates
Table 95. Merck & Co. Company Information
Table 96. Merck & Co. Description and Business Overview
Table 97. Merck & Co. Blood Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. Merck & Co. Blood Cancer Treatments Product
Table 99. Merck & Co. Recent Developments/Updates
Table 100. AstraZeneca Company Information
Table 101. AstraZeneca Description and Business Overview
Table 102. AstraZeneca Blood Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. AstraZeneca Blood Cancer Treatments Product
Table 104. AstraZeneca Recent Developments/Updates
Table 105. Pfizer Company Information
Table 106. Pfizer Description and Business Overview
Table 107. Pfizer Blood Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. Pfizer Blood Cancer Treatments Product
Table 109. Pfizer Recent Developments/Updates
Table 110. Amgen Company Information
Table 111. Amgen Description and Business Overview
Table 112. Amgen Blood Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 113. Amgen Blood Cancer Treatments Product
Table 114. Amgen Recent Developments/Updates
Table 115. Eli Lilly Company Information
Table 116. Eli Lilly Description and Business Overview
Table 117. Eli Lilly Blood Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 118. Eli Lilly Blood Cancer Treatments Product
Table 119. Eli Lilly Recent Developments/Updates
Table 120. AbbVie Company Information
Table 121. AbbVie Description and Business Overview
Table 122. AbbVie Blood Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 123. AbbVie Blood Cancer Treatments Product
Table 124. AbbVie Recent Developments/Updates
Table 125. Takeda Company Information
Table 126. Takeda Description and Business Overview
Table 127. Takeda Blood Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 128. Takeda Blood Cancer Treatments Product
Table 129. Takeda Recent Developments/Updates
Table 130. Astellas Company Information
Table 131. Astellas Description and Business Overview
Table 132. Astellas Blood Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 133. Astellas Blood Cancer Treatments Product
Table 134. Astellas Recent Developments/Updates
Table 135. Ipsen Company Information
Table 136. Ipsen Description and Business Overview
Table 137. Ipsen Blood Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 138. Ipsen Blood Cancer Treatments Product
Table 139. Ipsen Recent Developments/Updates
Table 140. Sanofi Company Information
Table 141. Sanofi Description and Business Overview
Table 142. Sanofi Blood Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 143. Sanofi Blood Cancer Treatments Product
Table 144. Sanofi Recent Developments/Updates
Table 145. Bayer Company Information
Table 146. Bayer Description and Business Overview
Table 147. Bayer Blood Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 148. Bayer Blood Cancer Treatments Product
Table 149. Bayer Recent Developments/Updates
Table 150. Biogen Idec Company Information
Table 151. Biogen Idec Description and Business Overview
Table 152. Biogen Idec Blood Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 153. Biogen Idec Blood Cancer Treatments Product
Table 154. Biogen Idec Recent Developments/Updates
Table 155. Teva Company Information
Table 156. Teva Description and Business Overview
Table 157. Teva Blood Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 158. Teva Blood Cancer Treatments Product
Table 159. Teva Recent Developments/Updates
Table 160. Otsuka Company Information
Table 161. Otsuka Description and Business Overview
Table 162. Otsuka Blood Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 163. Otsuka Blood Cancer Treatments Product
Table 164. Otsuka Recent Developments/Updates
Table 165. Eisai Company Information
Table 166. Eisai Description and Business Overview
Table 167. Eisai Blood Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 168. Eisai Blood Cancer Treatments Product
Table 169. Eisai Recent Developments/Updates
Table 170. Merck KGaA Company Information
Table 171. Merck KGaA Description and Business Overview
Table 172. Merck KGaA Blood Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 173. Merck KGaA Blood Cancer Treatments Product
Table 174. Merck KGaA Recent Developments/Updates
Table 175. Gilead Sciences Company Information
Table 176. Gilead Sciences Description and Business Overview
Table 177. Gilead Sciences Blood Cancer Treatments Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 178. Gilead Sciences Blood Cancer Treatments Product
Table 179. Gilead Sciences Recent Developments/Updates
Table 180. Key Raw Materials Lists
Table 181. Raw Materials Key Suppliers Lists
Table 182. Blood Cancer Treatments Distributors List
Table 183. Blood Cancer Treatments Customers List
Table 184. Blood Cancer Treatments Market Trends
Table 185. Blood Cancer Treatments Market Drivers
Table 186. Blood Cancer Treatments Market Challenges
Table 187. Blood Cancer Treatments Market Restraints
Table 188. Research Programs/Design for This Report
Table 189. Key Data Information from Secondary Sources
Table 190. Key Data Information from Primary Sources
Table 191. Authors List of This Report


List of Figures
Figure 1. Product Picture of Blood Cancer Treatments
Figure 2. Global Blood Cancer Treatments Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Blood Cancer Treatments Market Share by Type: 2025 & 2032
Figure 4. Chemotherapy Product Picture
Figure 5. Targeted Therapy Product Picture
Figure 6. Immunotherapy (Biologic Therapy) Product Picture
Figure 7. Hormonal Therapy Product Picture
Figure 8. Others Product Picture
Figure 9. Global Blood Cancer Treatments Market Value by Application (US$ Million), 2021–2032
Figure 10. Global Blood Cancer Treatments Market Share by Application: 2025 & 2032
Figure 11. Leukemia
Figure 12. lymphoma
Figure 13. Myeloma
Figure 14. Others
Figure 15. Global Blood Cancer Treatments Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 16. Global Blood Cancer Treatments Market Size (US$ Million), 2021–2032
Figure 17. Global Blood Cancer Treatments Sales (K Units), 2021–2032
Figure 18. Global Blood Cancer Treatments Average Price (US$/Unit), 2021–2032
Figure 19. Blood Cancer Treatments Report Years Considered
Figure 20. Blood Cancer Treatments Sales Share by Manufacturers in 2025
Figure 21. Global Blood Cancer Treatments Revenue Share by Manufacturers in 2025
Figure 22. Top 5 and Top 10 Global Blood Cancer Treatments Players: Market Share by Revenue in Blood Cancer Treatments in 2025
Figure 23. Blood Cancer Treatments Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 24. Global Blood Cancer Treatments Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 25. North America Blood Cancer Treatments Sales Market Share by Country (2021–2032)
Figure 26. North America Blood Cancer Treatments Revenue Market Share by Country (2021–2032)
Figure 27. United States Blood Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
Figure 28. Canada Blood Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. Europe Blood Cancer Treatments Sales Market Share by Country (2021–2032)
Figure 30. Europe Blood Cancer Treatments Revenue Market Share by Country (2021–2032)
Figure 31. Germany Blood Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. France Blood Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. U.K. Blood Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. Italy Blood Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Russia Blood Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. Asia Pacific Blood Cancer Treatments Sales Market Share by Region (2021–2032)
Figure 37. Asia Pacific Blood Cancer Treatments Revenue Market Share by Region (2021–2032)
Figure 38. China Blood Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. Japan Blood Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. South Korea Blood Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. India Blood Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Australia Blood Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. China Taiwan Blood Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Southeast Asia Blood Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Latin America Blood Cancer Treatments Sales Market Share by Country (2021–2032)
Figure 46. Latin America Blood Cancer Treatments Revenue Market Share by Country (2021–2032)
Figure 47. Mexico Blood Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Brazil Blood Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Argentina Blood Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Colombia Blood Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. Middle East and Africa Blood Cancer Treatments Sales Market Share by Country (2021–2032)
Figure 52. Middle East and Africa Blood Cancer Treatments Revenue Market Share by Country (2021–2032)
Figure 53. Turkey Blood Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. Saudi Arabia Blood Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
Figure 55. UAE Blood Cancer Treatments Revenue Growth Rate (US$ Million), 2021–2032
Figure 56. Global Sales Market Share of Blood Cancer Treatments by Type (2021–2032)
Figure 57. Global Revenue Market Share of Blood Cancer Treatments by Type (2021–2032)
Figure 58. Global Blood Cancer Treatments Price (US$/Unit) by Type (2021–2032)
Figure 59. Global Sales Market Share of Blood Cancer Treatments by Application (2021–2032)
Figure 60. Global Revenue Market Share of Blood Cancer Treatments by Application (2021–2032)
Figure 61. Global Blood Cancer Treatments Price (US$/Unit) by Application (2021–2032)
Figure 62. Blood Cancer Treatments Value Chain
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed